SME Instrument is part of the Horizon2020 programme and is a financing instrument promoted by the European Commission that aims to support innovative projects that have the ambition to grow, develop and internationalize through an innovation project with a European and global dimension.

In Phase 2, support is provided to innovation projects with high potential for growth and increased competitiveness, based on a strategic business plan. In order to be chosen, a highly competitive process must be carried out where hundreds of projects from all over Europe compete to achieve the seal of excellence that allows it to be chosen as a funded project. In this process, we have to highlight the help provided by the consultancy ATEKNEA SOLUTIONS and Acció de la Generalitat de Catalunya. Their contribution has been key to achieving one of the best scores in the selection process.

By way of summary, we are going to dedicate the subsidy obtained to the following activities in the next 24 months:

  • Expansion of clinical studies to hospitals in Madrid and Germany

One of the pillars of our project is to clinically demonstrate the functioning of the MJN-SERAS device. To this end, we have devoted a great deal of effort, both in terms of personal and financial resources, to the conduct of clinical trials. And this is so because only through these trials, we can demonstrate to the medical community that MJN-SERAS is able to function properly. It must be borne in mind that the solution we propose is unique in the world. MJN-SERAS is the first wearable device designed to continuously assess the risk of epileptic seizures through brain activity. MJN-SERAS has as final objective to launch a warning signal before a crisis to avoid accidents.

The scientific community has the obligation that any novelty in the field of health has demonstrated through trials that it fulfills its function . This requirement is even greater for cases such as ours as there is nothing on a clinical or commercial level to compare with. a very important part of the subsidy obtained to increase the validation of MJN-SERAS..

  • Help for marketing, internationalization and communication

MJN-SERAS will be a commercial reality in the first part of 2019. Our project aims to be an initiative that is sustainable over time and that combines both economic and social profitability . In order to achieve these objectives, we have to carry out all the necessary commercial and communication activities.

  • Evolution artificial intelligence of MJN-SERAS, Big-Data application

To continue the evolution of MJN-SERAS, and be able to reach more people, we have to increase the intelligence of our algorithms so that they are able to learn automatically from each case so, increase the reliability at the same time as increase the number of people who can use it . We will also initiate the use of Big-Data to try to discover why each case of epilepsy is unique and what factors influence each case.

We would like to emphasise that all the effort we are making does not pursue technical, scientific or management excellence per se. At MJN we understand that it is only from this excellence that we will be able to meet our true objective of improving the quality of life of people with epilepsy.

And finally, to say that we know that each case of epilepsy is unique and that we are committed to the proper functioning of MJN-SERAS. For this reason, we contractually guarantee that in all cases where our device does not fulfil its function, we will refund the purchase price less personalization and transport costs.

Thank you to the European Commission for the trust it has placed in us. And also to all those people who support us every day.

The MJN team.


Find out your risk of having an epileptic seizure at any time and place.

Leave a Reply

The user who fills in the information requested in this form declares to be entitled to do so and is solely responsible for the accuracy and completeness of the data and information entered, expressly exonerating MJN NEUROSERVEIS of any liability that may arise for this entity on the occasion of the information provided through this form.

Yes, I accept

L’usuari que complimenta la informació requerida al present formulari declara estar legitimat per això i es fa responsable exclusiu de la veracitat i integritat de les dades i informació que introdueix, exonerant expressament a MJN NEUROSERVEIS de qualsevol responsabilitat que es pugi generar per aquesta entitat amb ocasió de la informació facilitat a través del present formulari.

Si, accepto

El usuario que cumplimenta la información requerida en el presente formulario declara estar legitimado para ello y se hace responsable exclusivo de la veracidad e integridad de los datos e información que introduce, exonerando expresamente a MJN NEUROSERVEIS de cualquier responsabilidad que pudiera generarse para esta entidad con ocasión de la información facilitada a través del presente formulario.

Sí, acepto

Save the date

The next Saturday 21st of November at 4 pm, you will be able to know first hand our product: mjn-SERAS.
mjn-SERAS is a healthcare product that sends a warning signal when the risk of epileptic seizures is high, to the affected person and their trusted contacts.

Sign up now!

    mjn-SERAS is a medical device with CE marking according to the European Directive 93/42/EEC and the Royal Decree RD. 1591/2009.
    Contraindications: Do not use the product if you suffer from an infection in the ear canal or if you suffer from a skin lesion in the vicinity of the product's area of influence.
    Considerations: This medical product works with an APP only on Android phones. The results tested are 96% sensitivity and 94% specificity.

    Save the date

    El próximo sábado 21 de noviembre a las 4 de la tarde, podrás conocer de primera mano nuestro producto: mjn-SERAS.
    mjn-SERAS es un producto sanitario que lanza una señal de aviso cuando el riesgo de crisis de epilepsia es elevado, a la persona afectada y a sus contactos de confianza.


      mjn-SERAS es un producto sanitario con marcado CE conforme a la Directiva Europea 93/42/EEC y el Real Decreto RD. 1591/2009.
      Contraindicaciones: No usar el producto en caso de padecer una infección en el canal auditivo o en caso de padecer una lesión cutánea en las proximidades del área de influencia del producto.
      Consideraciones: Este producto sanitario funciona con una APP solo en teléfonos Android. Los resultados testeados son 96% de sensibilidad y 94% de especificidad.